Netarsudil Use After Descemetorhexis Without Endothelial Keratoplasty

Completed · Early Phase 1

Conditions studied: Fuchs' Endothelial Dystrophy, Cataract

In brief

Primary aim of the study is to determine whether a rho kinase inhibitor, Netarsudil, can speed corneal clearance after DWEK. Secondary aim of the study is to investigate whether patient factors, such as baseline age, pachymetry, or endothelial cell count influence response to Netarsudil.

Key facts

Study ID

NCT04057053

Run by

Massachusetts Eye and Ear Infirmary

People needed

10

Starts

2018-10-02

Expected to finish

2020-12-20

Last updated by the study team

2021-01-26

Who can join

Age: 50 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Cataract in both eyes
• Fuchs endothelial dystrophy in both eyes

You may not qualify if…

• History of ocular surgery in one eye and not the other
• History of significant ocular trauma/burn in one eye and not the other
• Inability to provide informed consent
• Inability to undergo eye surgery
• Inablity to use eye drops reliably

Where it is running

• Massachusetts Eye and Ear Infirmary — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.